Top 3 scientific issues facing biosimilar development

biosimilar, informatics, pharmacovigilance

Are you thinking about directing your R&D efforts in the direction of biosimilars?  Would knowing the scientific hurdles which are currently bottlenecking development aid in your decision making?  We posed this very question to over 200 individuals from a cross-section of the biosimilars industry and can provide you with an insight into this critical information.

And the results are in: the top 3 scientific challenges and issues facing biosimilar and biobetter development pipelines are;

  • Technological advances driving biosimilar development 
  • New Phase I requirements to supplement or complete original data package
  • Safety

What are your top challenges when trying to take your drugs to market?

DOWNLOAD the complete survey!


Interested in reading more on this topic? Take a look here:

Survey Download: Top challenges and opportunities in Biosimilar development

Top drivers fuelling industries biosimilar engagement today

Top strategic considerations when entering the biosimilars market

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D

Leave a Reply

Your email address will not be published. Required fields are marked *